Show simple item record

dc.contributor.author Kumar, Sahel
dc.contributor.author Gál, Zsófia
dc.contributor.author Gonda, Xénia
dc.contributor.author Huse, Robin J
dc.contributor.author Juhász, Gabriella
dc.contributor.author Bagdy, György
dc.contributor.author Petschner, Péter
dc.date.accessioned 2019-09-10T20:50:11Z
dc.date.available 2019-09-10T20:50:11Z
dc.date.issued 2019
dc.identifier 85064544254
dc.identifier.citation journalVolume=21;journalIssueNumber=1;journalTitle=NEUROPSYCHOPHARMACOLOGIA HUNGARICA;pagerange=26-35;journalAbbreviatedTitle=NEUROPSYCHOPHARM HUNG;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/7384
dc.description.abstract The review focuses on transcriptomic changes following treatment with serotonin reuptake inhibitor (SSRI) antidepressants. We aimed to overview results of the most established methods for the investigation of the gene expression alterations including northern blotting, in situ hybridization, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), microarray and RNAseq in various brain regions and after chronic treatment protocols. In spite of some measurable changes in serotonin system mRNA expression, serotonin transporter levels remained mostly unaltered following various treatment protocols. In contrast, tryptophan hydroxylase 2 appeared to be downregulated in serotonergic nuclei, and upregulated in the midbrain regions. Alterations in serotonin receptors lack clear conclusions and changes probably reflect animal strain/substance related- and brain region dependent effects. Brain derived neurotrophic factor was upregulated following many, but not all chronic treatment regimens. GABA and glutamate genes also showed heterogeneous changes, with a surprising NMDA receptor downregulation in areas including the striatum and amygdala, known to be involved in depressive states and stress reactions. The review of the above studies suggests alterations in multiple processes, reflecting the heterogeneity of the action depending on brain area and type of SSRI, and raises the possibility of a novel grouping of antidepressant medications based on their chronic molecular profile rather than on their initial actions.
dc.format.extent 26-35
dc.title Krónikus szelektív szerotoninvisszavétel-gátló kezelés hatására bekövetkező transzkripciós változások: az állatkísérletek áttekintése
dc.type Journal Article
dc.date.updated 2019-08-02T07:45:58Z
dc.language.rfc3066 en
dc.rights.holder NULL
dc.identifier.mtmt 30629425
dc.identifier.pubmed 30962407
dc.contributor.department SE/GYTK/Gyógyszerhatástani Intézet
dc.contributor.department SE/GYTK/GYHATAS/MTA-SE Neuropszichofarmakológiai és Neurokémiai Kutatócsoport
dc.contributor.department SE/GYTK/GYHATAS/NAP-A-SE Új Antidepresszív Gyógyszercélpont Kutatócsoport
dc.contributor.department SE/AOK/K/Pszichiátriai és Pszichoterápiás Klinika
dc.contributor.department SE/GYTK/GYHATAS/MTA-SE-NAP B Genetikai Agyi Képalkotó Migrén Kutató Csoport
dc.contributor.institution Semmelweis Egyetem
dc.mtmt.swordnote Journal Article; Review


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account